Radiation-induced sarcoma (RIS) has been reported as a late secondary malignancy
following radiotherapy for various types of cancer with a median latency of 10 years. We …

ABSTRACT The PD-1/PD-L1 axis is characterized as an important checkpoint of immune
activation, particularly through negatively regulating T cell function. Although accumulated …

Until recently, patients with relapsed Hodgkin's lymphoma after brentuximab vedotin (Bv)
treatments had poor treatment outcomes. Checkpoint inhibitors such as nivolumab and …

Most patients with Hodgkin lymphoma (HL) get a remission after induction chemotherapy
with or without radiation therapy (RT). However, relapse rates range from 10–20% in cases …

Background: Patients (pts) with relapsed or primary refractory (r/r) Hodgkin lymphoma (HL)
who do not achieve complete response (CR) to PD-1 inhibitors have limited options …

Results Soft tissue (STS) and bone sarcomas (BS) occurred in 18 (STS= 12 patients, BS= 6
patients) of 930 HL patients (1.9%), comprising 18% of all SMNs. Of these 18 patients, 12 …

Hodgkin lymphoma is a highly curable malignancy involving lymph nodes and the lymphatic
system. Even at late stage disease, about 70% of patients will be cured with standard first …

11040 Background: RIS is a rare subset of soft tissue sarcoma (STS) with poor prognosis
and limited treatment options. We hypothesize that subsets of STS that carry genomic …

Although it had been known for some time that radiation therapy (RT) was carcinogenic,
there were few reports documenting an increase in second malignant neoplasms (SMN) in …

Purpose/Objective (s) The management of relapsed/refractory pediatric Hodgkin lymphoma
(rrpHL) is complex. Clear indications do not exist for consolidative radiotherapy (CRT), and …